Vanderbilt researchers designed micelle “packets” to selectively deliver anti-cancer drugs to breast cancer cells.

Vanderbilt-Ingram Cancer Center investigators have identified the mechanisms used by a gene and its binding protein to drive tumor growth in several forms of cancer, including non-small cell lung cancer.

Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks.

Daniel Barocas, M.D., MPH, assistant professor of Urologic Surgery at Vanderbilt University Medical Center, was recently named a representative on the Commission on Cancer.

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

Two Vanderbilt-Ingram Cancer Center (VICC) leaders have been named to a panel of the Institute of Medicine (IOM) to help shape national policies on the use of biomarkers for targeted cancer therapies.

A specific gene expression profile represents a novel, biologically relevant “signature” for identifying colon cancers with high risk of metastatic recurrence, Vanderbilt researchers have found.